Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Preservation: Analytical-grade 0.9% Benzyl Alcohol for long-term bacteriostatic protection
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
Laser-assisted drug delivery is an evolving technology with potentially broad clinical applications
The problem starts when production increases beyond what your body can handle quietly
These treatments helped her thrive in many ways
The bound proteins were eluted with 50 l of binding buffer containing 2% SDS at 50 C for 10 min
:format(webp))
